



SANJIVANI PARANTERAL LIMITED

205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai - 400 078, Maharashtra

Date: 14th May, 2026

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip Code: 531569

Sub: Investor Presentation for the Fourth Quarter and Financial Year Ended 31st March, 2026

Dear Sir/ Madam,

Please find enclosed herewith Investor Presentation of Sanjivani Paranteral Limited highlighting the performance of the Company during the Fourth Quarter and Financial Year Ended 31st March, 2026.

Kindly take the above information on your records.

Thanking You,
Yours Faithfully,

For Sanjivani Paranteral Limited

Ravikumar Bogam
Company Secretary Cum Compliance Officer



SANJIVANI
PARANTERAL LTD

INVESTOR PRESENTATION

Q4 & FY26



Table of Contents

05
Market Overview

08
About The Company

14
Manufacturing
Facilities

17
CDMO Key Clients

19
Company's Segment &
Revenue Mix

23
Global Footprint

25
Product Portfolio

29
Financials

37
Stock Information



Q4 FY26



Revenue from Operations
(down 42.2% Y-o-Y)

INR 105.1 mn



EBITDA*
(down by 45.6% Y-o-Y)

INR 16.6 mn



PAT
(down by 57.2% Y-o-Y)

INR 9.4 mn



Domestic & Export
(share in revenue)

14.7% & 85.3%

*EBITDA: includes other income

FY26



Revenue from Operations
(down 7.6% Y-o-Y)

INR 647.6 mn



EBITDA*
(down 8.1% Y-o-Y)

INR 106.3 mn



PAT
(14.6% Y-o-Y)

INR 69.2 mn



Domestic & Export
(share in revenue)

21.5% & 78.5%

*EBITDA: includes other income



MARKET OVERVIEW




Use of medicines region wise, Defined Daily Doses (DDD)


Country Name/Year	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E	2027E	2028E	CAGR 2024-2028
Asia-Pacific	451	461	477	507	547	538	559	580	598	618	637	3.4%
Latin America	342	357	438	447	448	461	473	484	489	496	506	1.9%
Western Europe	435	445	444	448	469	463	470	476	481	485	488	1.1%
India	354	359	370	400	390	399	412	428	443	458	474	3.5%
Africa & Middle East	385	395	393	428	425	410	413	424	434	442	451	1.9%
Eastern Europe	332	339	341	358	369	362	370	377	384	388	391	1.6%
China	255	279	271	301	308	308	323	337	349	359	369	3.7%
North America	270	272	270	281	290	290	294	299	303	306	309	1.3%
Japan	141	143	141	145	147	148	149	151	152	152	153	0.6%
Total	2,964	3,049	3,144	3,316	3,394	3,378	3,465	3,556	3,633	3,704	3,778	

Source: IQVIA Institute, Dec 2023.


Defined Daily Doses (DDD) in billions



Global use of medicines



Global spending on medicine



Source: IQVIA Institute, Dec 2023.



ABOUT THE COMPANY



Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.



**WHO-GMP/
DIGEMID / DDA**

Certified
Plants



2

Manufacturing
Facilities



25
Countries

Geographical
Reach



~75%

Exports
Revenue



25+ years

Experience



720
million

Annual Tablet
Capacity



84 million

Annual Ampoules
Capacity



12 million

Annual Liquid
injectables Capacity



120 million

Annual B Lactam
Tablet Capacity



180 million

Annual B Lactam
Capsule Capacity



72 million


Annual Capsule
Capacity



48 million

Annual Vial
Capacity

Significant Milestones of Sanjivani Paranteral Ltd.



Years are mentioned as calendar years



To be one of India's best research-based pharmaceutical companies, through focus on quality and customer satisfaction.

To bring forth a new paradigm of products & services which lead to unprecedented growth for our stakeholders, customers, strategic partners & team members.

To grow the company on the foundation of Passion, Performance & Partnership.



Creating a world-class organization offering products, services & paradigms that open up new worlds of opportunities.



1. Quality

Products that we are proud of

2. Customer Satisfaction


Ensuring customer delight

3. Growth for all stakeholders

Exceeding stakeholders' expectations is our success mantra

4. Professionalism

People you love to work with. A culture of innovative thinking, backed by disciplined execution





Mr. Ashwani Khemka
Chairman & Managing Director



Mr. Basant Srivastava
Director



Mr. Srivardhan Khemka
Executive Director



Mr. Abhay Shah
Independent Director



Ms. Monika A. Singhania
Independent Director



Mr. Pritesh Jain
Chief Financial Officer



MANUFACTURING FACILITIES









SANJIVANI
PARANTERAL LTD

CDMO KEY CLIENTS



Injectables



Oral & Nutraceuticals










COMPANY'S SEGMENT & REVENUE MIX




Product Category Mix (%) | Standalone




Q4 FY26




Q4 FY25



FY26




FY25




Region-wise Mix (%)


Q4 FY26




Q4 FY25



FY26





FY25





GLOBAL FOOTPRINT







Dehradun, Navi Mumbai, Pune & Prague



PRODUCT PORTFOLIO





Urologics



Anesthetics



Anesthetics



Anti Convulsants



Anti Thyroid Agent



Anti Fungal




Anti Emetics



Anti Depressants



Anti Histamines



Anti Diabetic



Anti-lepemic Agent



Anti Fibrinolytics



Anti-bacterials



Anti-spasmodic



Anti Hypertensive Agent



Vitamin Supplement



Skeletal Muscle Relaxant



Analgesic & Anti Histaminic



Non-opioid Analgesics



Antacids



Antiseptics



Nsaids



Corticosteroids



Diuretics



Immunosuppressants



Narcotic



Hormone



Topical Corticosteroids



Anti Anxiety



Antibiotic



Antipsychotic



Anti Viral



Narcotics



Anti- Muscle Relaxant






FINANCIALS




Segment-wise Revenue

(Injectables, Oral & Nutraceuticals) INR Mn


INJECTABLES



ORALS




NUTRACEUTICALS




Segment-wise Revenue

(Injectables, Oral & Nutraceuticals) INR Mn


INJECTABLES



ORALS




NUTRACEUTICALS




Revenue, EBITDA & Margin, PAT & Margin

INR Mn.


REVENUE*




EBITDA** & EBITDA Margin



PBT & PBT Margin



PAT & PAT Margin




*Revenue from Operations (excluding other income) **EBITDA: Including other income

Quarterly Financials


Revenue, EBITDA & Margin, PAT & Margin

INR Mn.


REVENUE*




EBITDA** & EBITDA Margin



PBT & PBT Margin



PAT & PAT Margin




*Revenue from Operations (excluding other income) **EBITDA: Including other income

Q4 FY26 Profit & Loss Statement


Particulars	Q4 FY26	Q4 FY25	YoY%	Q3 FY26	QoQ%	FY26	FY25	YoY%
Revenue From Operations	105.1	181.8	-42.2%	208.6	-49.6%	647.6	701.0	-7.6%
Other Income	7.47	4.27	75.0%	2.91	157.1%	12.4	12.1	2.0%
Total Income	112.6	186.1	-39.5%	211.5	-46.8%	660.0	713.1	-7.4%
COGS	62.9	93.9	-33.0%	141.9	-55.7%	419.2	404.8	3.6%
Gross Profit	49.7	92.1	-46.1%	69.7	-28.7%	240.8	308.3	-21.9%
Gross Margin (%)	47.3%	50.7%	-341 bps	33.4%	1387 bps	37.2%	44.0%	-680 bps
Employee Benefit Exp.	16.9	21.1	-19.6%	16.2	4.3%	63.31	64.93	-2.5%
Other Expenses	16.2	40.6	-60.2%	14.6	10.7%	71.10	127.62	-44.3%
EBITDA incl. other income	16.6	30.5	-45.6%	38.8	-57.3%	106.3	115.7	-8.1%
EBITDA Margin (%)	15.8%	16.8%	-99 bps	18.6%	-284 bps	16.4%	16.5%	-9 bps
Depreciation	3.5	1.8	87.8%	1.9	84.9%	8.6	6.2	39.2%
Finance Cost	0.6	2.0	-69.4%	2.1	-70.3%	5.4	5.9	-9.0%
PBT	12.5	26.6	-53.0%	34.9	-64.2%	92.3	103.6	-10.9%
Tax	3.13	4.67	-33.0%	8.72	-64.1%	23.1	22.6	2.2%
PAT	9.4	21.9	-57.3%	26.2	-64.2%	69.2	81.0	-14.5%
PAT Margin (%)	8.3%	11.8%	-346 bps	12.4%	-404 bps	10.5%	11.4%	-87 bps
Basic EPS (in Rs.)	0.80	1.84	-56.5%	2.13	-126.5%	5.67	6.89	-17.7%
Diluted EPS (in Rs.)	0.80	1.62	-50.6%	2.13	-123.8%	5.67	6.67	-15.0%

Q4 FY26 Profit & Loss Statement (Consolidated)

Particulars	Q4 FY26	Q4 FY25	YoY%	Q3 FY26	QoQ%	FY26	FY25	YoY%
Revenue From Operations	132.1	181.8	-27.3%	220.6	-40.1%	686.7	701.0	-2.0%
Other Income	6.0	4.3	39.1%	3.0	101.9%	10.9	12.2	-10.2%
Total Income	138.1	186.1	-25.8%	223.6	-38.2%	697.6	713.1	-2.2%
COGS	73.9	93.9	-21.3%	147.3	-49.8%	435.8	404.8	7.6%
Gross Profit	64.2	92.2	-30.4%	76.2	-15.8%	261.8	308.3	-15.1%
Gross Margin (%)	48.6%	50.7%	-213 bps	34.6%	1401 bps	38.1%	44.0%	-585 bps
Employee Benefit Exp.	22.41	21.07	6.4%	17.56	27.6%	70.10	64.93	8.0%
Other Expenses	20.02	40.69	-50.8%	17.34	15.5%	77.70	127.71	-39.2%
EBITDA incl. other income	21.7	30.4	-28.5%	41.3	-47.4%	114.0	115.7	-1.4%
EBITDA Margin (%)	16.4%	16.7%	-27 bps	18.7%	-229 bps	16.6%	16.5%	10 bps
Depreciation	6.6	1.8	257.2%	2.3	189.0%	12.2	6.2	95.9%
Finance Cost	3.1	2.0	55.1%	2.1	50.5%	7.9	5.9	33.5%
PBT	12.0	26.5	-54.7%	37.0	-67.5%	93.9	103.5	-9.3%
Tax	6.5	4.7	39.9%	9.2	-29.1%	27.0	22.6	19.5%
PAT	5.5	21.9	-74.9%	27.8	-80.2%	66.9	80.9	-17.3%
PAT Margin (%)	4.0%	11.7%	-778 bps	12.4%	-845 bps	9.6%	11.4%	-175 bps
Basic EPS (in Rs.)	0.49	1.84	-73.4%	2.21	-133.2%	5.49	6.89	-20.3%
Diluted EPS (in Rs.)	0.49	1.61	-69.6%	2.21	-131.5%	5.49	6.66	-17.6%




Shareholding Pattern % as on 31st March 2026



Stock Information (as on 31st March 2026)

Market Cap. (in Bn)	1.6
Stock Price	133
52 Week (High / Low)	269 / 133
BSE – Symbol	531569
Free Float (No. of Shares)	84,03,816
Average Daily Volume (3 months) - BSE	9,800





 **SANJIVANI**
PARANTERAL LTD

THANK YOU

Sanjivani Paranteral Limited

205, P.N.Kothari Industrial Estate, L.B.S.
Marg Bhandup (W), Mumbai- 400078, India.

Ph: +91-22-20812600 / 25620515

Email: corporate@sanjivani.co.in